Leo Brokerage’s Avalo Therapeutics AVTX Stock Holding History

Leo Brokerage’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-22	Closed	-$45K	–	185
2022 Q1	$45K	Buy	+22	New	+$55.3K	0.01%	241

Other funds holding AVTX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Leo Brokerage's AVTX Position: Q2 2022 in Review

Leo Brokerage sold out of Avalo Therapeutics (AVTX) in Q2 2022, closing a stake of 22 shares — an estimated $45K sold.

Leo Brokerage first reported a position in AVTX in Q1 2022 and held it in 1 quarter. The position peaked at $45K in Q1 2022. 43 funds tracked by Wall St. Rank hold AVTX as of Q2 2022.

Leo Brokerage reported no remaining Avalo Therapeutics position as of Q2 2022 after selling out during the quarter.
Leo Brokerage sold 22 Avalo Therapeutics shares in Q2 2022, an estimated $45K.
Leo Brokerage first reported a position in Avalo Therapeutics in Q1 2022 and held it in 1 quarter.
Leo Brokerage's Avalo Therapeutics position peaked at $45K in Q1 2022.
43 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2022.

Based on Leo Brokerage's 13F filing for Q2 2022, filed 11 Jul 2022.